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Abstract
Background: Patients infected with the novel coronavirus
SARS-CoV-2 are frequently hospitalized with communityacquired pneumonia (CAP). The objective of this study was
to define the clinical characteristics and outcomes of hospitalized patients with SARS-CoV-2 CAP in the city of Louisville,
KY.
Methods: This was a retrospective observational study of
700 patients with SARS-CoV-2 infection hospitalized at eight
of the adult hospitals in the city of Louisville. Patients with 1)
a positive RT-PCR for SARS-CoV-2, 2) fever, cough, or shortness of breath, and 3) an infiltrate on chest imaging were
defined as having SARS-CoV-2 CAP. Demographic characteristics of the study population were compared with census data from the city of Louisville. For each patient, more
than 500 variables were abstracted from electronic medical
records and recorded using Research Electronic Data Capture software. Data were analyzed by descriptive and inferential statistics using R version 3.4.0.

Introduction
Coronavirus disease 2019 (COVID-19) is a multisystem
disease produced by the novel coronavirus SARS-CoV2. COVID-19 manifests usually as an influenza-like
syndrome due to multiplication of SARS-CoV-2, primarily in the epithelial cells of the upper respiratory
tract. More severe disease occurs when the virus invades and multiplies in the lower respiratory tract particularly in alveolar epithelial type II cells.[1] At this
stage the patient will present with a clinical syndrome
of community-acquired pneumonia (CAP). SARS-CoV2 CAP is a common clinical presentation in hospiULJRI | https://ir.library.louisville.edu/jri/vol4/iss1/72

Results: SARS-CoV-2 CAP was identified in 632 (90%) patients hospitalized with COVID-19. The median age of the patients was 63 years, 53% were females, 31% were black, and
12% were Hispanic. The most frequent comorbidities were
hypertension (56%), obesity (50%), and diabetes (33%). Mortality was 17% for the total population and 34% for the 249
patients admitted to ICU. For each category of race, ethnicity, or comorbidity, the proportion of hospitalized patients with
SARS-CoV-2 CAP was significantly different compared to the
Louisville population (P <0.001).
Conclusion: Patients of black race, Hispanic ethnicity, and
patients with a history of hypertension, obesity, or diabetes
are overrepresented among hospitalized patients with SARSCoV-2 CAP compared to the Louisville population. Hospitalized patients with SARS-CoV-2 CAP are likely to require ICU
care, with death occurring in approximately one of six hospitalizations.

talized patients with COVID-19. If the infection advances, viral replication accelerates, and the epithelialendothelial barrier integrity is compromised. At this
next stage the patient may develop acute respiratory
distress syndrome (ARDS) due to pulmonary edema
filling the alveolar spaces with hyaline membrane formation.[1]
A significant amount of literature has been published
describing the characteristics and outcomes of patients
hospitalized with COVID-19, but clinical characteristics of patients with SARS-CoV-2 CAP, as well as their
clinical outcomes, has been described in a limited num1
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ber of studies. Before the development of the COVID19 pandemic, we completed a population-based study
of all hospitalized patients with CAP in the city of
Louisville, KY. We prospectively enrolled all consecutive patients with CAP hospitalized to any of the adult
hospitals in the city of Louisville during a period of 2
years.[2] Taking advantage of this well-established citywide clinical research network, we evaluated the first
700 hospitalized patients with a diagnosis of COVID19 with the objective to define the clinical characteristics and outcomes of hospitalized patients with SARSCoV-2 CAP in the city of Louisville.

Clinical presentation

Methods

Stage 2: SARS-CoV-2 Mild Infection. A patient with
positive SARS-CoV-2 RT-PCR and COVID-19 related
symptoms but without evidence of pulmonary infiltrates at chest imaging (e.g. no evidence of CAP).

Study design, subjects, and setting
This was a retrospective observational study of the first
700 patients with a diagnosis of SARS-CoV-2 hospitalized to any of the eight adult hospitals in the city
of Louisville, KY. The study started on March 5 2020,
when the first hospitalized patient with COVID-19 was
identified in Louisville and ended on July 1 2020. Patients’ follow-up ceased at hospital discharge.
Data collection
Data were abstracted from hospital electronic medical records. Collected data included patient age, sex,
race, ethnicity, body mass index, residence, medical
and social history, physical examination findings, laboratory findings, chest radiographs and chest CT findings, medications, intensive care unit (ICU) admission,
and need for mechanical ventilation. Race was categorized as black, white, and other. Ethnic group was categorized as Hispanic or non-Hispanic. Race and ethnicity were treated independently for analysis.
Study definitions
SARS-CoV-2 Infection: A patient hospitalized with a
positive SARS-CoV-2 reverse transcriptase polymerase
chain reaction (RT-PCR) from a nasopharyngeal swab
or other respiratory sample.
SARS-CoV-2 CAP: A patient hospitalized with SARSCoV-2 infection with fever, cough, or shortness of
breath, and with evidence of pulmonary infiltrates at
chest radiograph or chest computer tomography scan
(CT-scan).
SARS-CoV-2 CAP with ARDS: A patient with SARSCoV-2 CAP with evidence of acute respiratory distress
syndrome (ARDS) define as bilateral opacities on a
chest radiograph or computed tomographic (CT) scan
not fully explained by cardiac failure or fluid overload
with PaO2/FiO2 ≤300 mmHg, on ventilator settings
that include positive end-expiratory pressure (PEEP)
≥5 cm H2O.[3]
ULJRI | https://ir.library.louisville.edu/jri/vol4/iss1/72

The National Institutes of Health (NIH) guidelines for
COVID-19 classified adults with SARS-CoV-2 infection
in several severity of illness categories.[4] Using the
NIH model, we classified the clinical presentation of
hospitalized patients with COVID-19 in 9 stages. The
following definitions were used:
Stage 1: SARS-CoV-2 Asymptomatic Infection. A
patient with positive SARS-CoV-2 RT-PCR and no
COVID-19 related symptoms.

Stage 3: SARS-CoV-2 CAP with no supplemental oxygen. A patient with SARS-CoV-2 CAP not receiving
supplemental oxygen.
Stage 4: SARS-CoV-2 CAP and low-flow supplemental oxygen. A patient with SARS-CoV-2 CAP receiving
supplemental oxygen delivered by a low-flow system
(e.g. nasal cannula).
Stage 5: SARS-CoV-2 CAP and high-flow supplemental oxygen or non-invasive ventilation. A patient with
SARS-CoV-2 CAP receiving supplemental oxygen delivered by a high-flow system (e.g. high-flow nasal cannula) or non-invasive ventilation.
Stage 6: SARS-CoV-2 CAP and mechanical ventilation . A patient with SARS-CoV-2 CAP intubated receiving invasive mechanical ventilation.
Stage 7: SARS-CoV-2 CAP and Mild ARDS. A patient
with SARS-CoV-2 CAP on mechanical ventilation and
development of ARDS with a PaO2/FiO2 >200 mmHg,
but ≤300 mmHg.
Stage 8: SARS-CoV-2 CAP and Moderate ARDS. A
patient with SARS-CoV-2 CAP on mechanical ventilation and development of ARDS with a PaO2/FiO2
>100 mmHg, but ≤200 mmHg.
Stage 9: SARS-CoV-2 CAP and Severe ARDS. A patient with SARS-CoV-2 CAP on mechanical ventilation
and development of ARDS with a PaO2/FiO2 is ≤100
mmHg.
Severity of disease and mortality prediction
Severity of SARS-CoV-2 CAP at time of hospitalization
and mortality prediction was evaluated using two well
established CAP scores, the pneumonia severity index
(PSI) score and the CURB-65 score.[5,6].
2
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Relative SARS-CoV-2 RNA levels at time of hospitalization were estimated using the number of cycles in the
RT-PCR assay needed to amplify viral RNA to reach
a detectable level (cycle threshold). Levels of relative
SARS-CoV-2 RNA were classified as low, intermediate
and high.

graphics were performed using one-sample t-tests of
proportions, with null values equal to the Louisville
proportion, taken from the 2017 Behavioral Risk Factor Surveillance System (BRFSS) Smart Data database
and the 2019 American Community Survey 5-year estimates.[8,9] Analyses were performed with R version
3.4.0. P-values were 2-sided, with statistical significance set at P<0.05.

Geospatial epidemiology

Study coordinating center

The geomasked location of the home address of each
patient with SARS-CoV-2 CAP who was enrolled in
the study was obtained through the US Census Bureau website.[7] A kernel density heatmap was created using each patient’s address at the time of SARSCoV-2 CAP hospitalization. Areas of elevated relative
risk of contracting SARS-CoV-2 CAP based on underlying population density were identified using Kuldorff’s
spatial scan statistic.

The Center of Excellence for Research in Infectious Diseases (CERID) located at the University of Louisville
Division of Infectious Diseases, directed all operations of the study (CERIDLouisville.org). Members
of CERID developed the study data collection form
and the study database, collected data from hospital
electronic medical records and recorded data into the
study database. Data were collected and managed using REDCap electronic data capture tools hosted at the
University of Louisville. REDCap (Research Electronic
Data Capture) is a secure, web-based software platform
designed to support data capture for research studies,
providing an intuitive interface for validated data capture.[10] The CERID data quality team performed quality control of collected data. After all data queries were
resolved, the study database was locked for data analysis.

Cardiac and cardiovascular events
The following cardiac or cardiovascular events that
were present at the time of admission or developed
during hospitalization were collected: development of
heart failure, cardiac arrest, cardiogenic shock, acute
myocardial infarction, pulmonary edema, new arrhythmia, acute worsening of a chronic arrhythmia, cerebrovascular accident, pulmonary embolism, myocarditis, and deep vein thrombosis.
Co-infections
A patient with an isolated micro-organism from blood,
respiratory, or urine samples was defined as having a
co-infection. Community-acquired co-infections were
defined as identification of micro-organisms during the
first 3 days of hospital admission. Hospital-acquired
co-infections were defined as micro-organisms identified more than 3 days after hospital admission.
Clinical outcomes
Patients who were discharged alive were considered as
clinical successes and patients who died during hospitalization were considered as clinical failures. Binary
outcomes evaluated included need for invasive mechanical ventilation, admission to ICU, septic shock,
ARDS, and death. Time-to-event outcomes evaluated
included time to hospital discharge, time to initiation
of mechanical ventilation, time to ICU admission, time
to septic shock, time to ARDS, and time to death.
Statistical analysis
Continuous patient characteristics were summarized as
medians and interquartile ranges and categorical patient characteristics were summarized as frequencies
and percentages. Comparisons to Louisville demoULJRI | https://ir.library.louisville.edu/jri/vol4/iss1/72

Human subjects protection
The study was approved by the Institutional Review
Board (IRB) at the University of Louisville Human Subjects Research Protection Program Office (IRB number
20.0257) and by the research offices at each participating hospital. The study was exempt from informed
consent.

Results
Study population and clinical presentation
From a total of 700 patients hospitalized with COVID19, a total of 632 patients (90%) were hospitalized with
SARS-CoV-2 CAP. A bar chart describing the patients’
clinical presentation at time of hospitalization is depicted in Figure 1. The most common clinical presentation was SARS-CoV-2 CAP in patients not receiving
supplemental oxygen (stage 3). The primary clinical
diagnoses at time of hospitalization for 68 patients in
stages 1 and 2 (patients without SARS-CoV-2 CAP) included labor, trauma, and urinary tract infections. Demographics and comorbidities for hospitalized patients
with SARS-CoV-2 CAP are depicted in Table 1.
Comparisons of SARS-CoV-2 CAP patients’ demographics to the Louisville population are shown in Figure 2. Comparisons of SARS-CoV-2 CAP patients’
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Figure 1. Study bar chart indicating the number of COVID-19 hospitalized patients in each one of the nine stages of clinical presentation.

Figure 2. Comparison of patient demographics to those of the city of Louisville. All data are reported as percentage of the population in the
demographic.

ULJRI | https://ir.library.louisville.edu/jri/vol4/iss1/72
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Table 1. Patient demographics and medical history.

Characteristic
Total patients
Age (median [IQR])
Sex: Male
Race
Black
White
Other
Hispanic
Smoking history
Never
Current
Former
Hypertension
Obesity
Diabetes
Renal disease
Heart failure
Coronary artery disease
COPD
Cerebrovascular disease
Asthma
Obstructive sleep apnea
Neoplastic disease (active or within the last year)
Other immunocompromising condition or therapies
Liver disease (non-cirrhotic)
Cirrhosis

n (%)∗
632
63 [48, 74]
294 (47)
198 (31)
343 (54)
90 (14)
74 (12)
404 (64)
58 (9)
170 (27)
352 (56)
315 (50)
214 (33)
119 (19)
99 (16)
95 (15)
96 (15)
86 (14)
67 (11)
60 (9)
45 (7)
29 (5)
21 (3)
8 (1)

Abbreviations: COPD, chronic obstructive pulmonary disorder;
IQR, interquartile range.
∗ Except where otherwise specified.

Figure 3. Comparison of patient comorbidities to those of the city of Louisville. All data are reported as percentage of the population with the
comorbidity.
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Figure 4. Histogram depicting the number of patients with SARS-CoV-2 CAP per age group.

Figure 5. Comparison of percentage distribution of SARS-CoV-2 CAP patient age to the Louisville population (left) patients hospitalized with
SARS-CoV-2 CAP, (right) the adult population of Louisville.
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Table 2. Signs and symptoms for patient hospitalized
with SARS-CoV-2 CAP.

Sign/symptom
Total patients
Fever or subjective fever
Cough
Dyspnea (shortness of breath)
Fatigue
Muscle ache (myalgia)
Nausea
Diarrhea
Sputum production
Vomiting
Chest pain/tightness
Confusion
Headache
Sore throat
Nasal congestion
Dizziness
Rhinorrhea (runny nose)
Anosmia
Agusia
Hemoptysis (blood in sputum)
Constipation

n (%)
632
436 (69)
425 (67)
407 (64)
218 (34)
160 (25)
139 (22)
114 (18)
95 (15)
79 (12)
78 (12)
71 (11)
71 (11)
52 (8)
52 (8)
42 (7)
21 (3)
15 (2)
15 (2)
7 (1)
4 (1)

Table 3. Vital signs and laboratory values. The third column describes the
number of patients for whom data were available.

Variable
Heart rate (beats/min)
Respiratory rate (breaths/min)
Systolic blood pressure (mmHg)
Diastolic blood pressure (mmHg)
Temperature (°C)
SpO2/FiO2
PaO2/FiO2
WBC×1,000 per uL
Neutrophils×1,000 per uL
Lymphocytes×1,000 per uL
Neutrophil/lymphocyte
Hematocrit (%)
Glucose (mg/dL)
Blood urea nitrogen (mg/dL)
Creatinine (mg/dL)
Ferritin (ng/dL)
Procalcitonin (ug/L)
Lactate (mmol/L)
D-Dimer (ng/mL)
IL-6 (pg/mL)
C-reactive protein (mg/L)

Median [IQR]

n

96.5 [82.0, 111.0]
22.0 [18.0, 27.0]
121.0 [106.0, 140.2]
67.5 [57.0, 80.0]
37.7 [37.0, 38.7]
428.6 [290.6, 452.4]
187.2 [99.2, 297.7]
6.3 [4.6, 8.8]
4.6 [3.0, 7.4]
1.0 [0.7, 1.4]
4.5 [2.7, 7.8]
38.8 [35.2, 42.4]
123.0 [104.0, 166.0]
17.0 [11.0, 28.2]
1.0 [0.7, 1.4]
398.0 [176.0, 891.0]
0.1 [0.1, 0.4]
1.3 [1.1, 1.8]
736.0 [388.5, 1517.0]
58.2 [29.6, 131.3]
79.3 [38.0, 170.1]

632
632
632
632
632
631
238
627
610
615
609
627
629
626
627
435
504
465
447
198
436

Abbreviations: IQR, interquartile range; WBC, white blood cell
count.

comorbidities to the Louisville population are shown
in Figure 3. All comparisons between patient demographics and comorbidities to the Louisville population were statistically significant (P<0.001). The age
distribution showing the number of adults hospitalized
with SARS-CoV-2 CAP is depicted in Figure 4. A comparison of the percentage distribution of age groups between adults hospitalized with SARS-CoV-2 CAP and
the adult Louisville population is shown in Figure 5.
Signs and symptoms in patients with SARS-CoV-2 CAP
are depicted in Table 2. Median time from symptoms
onset to hospitalization was 4 days.
Vital signs and laboratory values for patients hospitalized with SARS-CoV-2 CAP at admission are depicted
in Table 3.
The characteristic chest CT-scans imaging of diffuse,
peripheral ground-glass opacities were present in 324
of 439 (74%) patients with chest CT performed.
Medications used in adults hospitalized with SARSCoV-2 CAP during hospitalization are depicted in Table 4.
Severity of disease and associated mortality

SARS-CoV-2 RNA levels
Cycle threshold (CT) values were available for a total
405 SARS-CoV-2 CAP patients. For these patients, the
lowest CT value from the N1, N2, and N3 genes was
used to represent the relative viral RNA levels, as a
lower CT value indicates a high viral load. CT values
are depicted in Figure 7.
Geospatial epidemiology
The kernel density heatmap created using each patient’s home address at the time of hospitalization due
to SARS-CoV-2 CAP is depicted in Figure 8.
Cardiac and cardiovascular events
A total of 120 patients (19%) developed cardiac or cardiovascular events. The list of cardiac and cardiovascular events is depicted on Table 5.
Co-infections
A total of 67 SARS-CoV-2 CAP patients had coinfections.
The list of patients with communityacquired (n=25) and hospital-acquired (n=42) coinfections is depicted on Table 6. For each type of coinfection, the culture sites were characterized.

The severity of CAP at time of hospitalization according to CURB-65 and PSI scores with associated mortality per class or score are depicted in Figure 6.

ULJRI | https://ir.library.louisville.edu/jri/vol4/iss1/72
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Table 4. Medications for treatment of SARS-CoV-2 CAP.

Medication
Total patients
Azithromycin
Low molecular weight heparin
Hydroxychloroquine
Steroid
Heparin
Convalescent plasma
Remdesivir

n (%)
632
398 (63)
394 (62)
239 (38)
145 (23)
114 (19)
50 (8)
31 (5)

Clinical outcomes
From the total population of 632 patients hospitalized
with SARS-CoV-2 CAP, clinical success (discharged
alive) was documented in 527 (83%) patients and clinical failure (died during hospitalization) in 105 (17%)
patients. The median length of hospital stay was 7
days. Time to hospital discharge and time to in-hospital
death is depicted in Figure 9A and 9B. A total of 249 patients were admitted to the ICU, with 124 admitted on
the first day. A total of 159 patients required mechanical ventilation. Mortality among patients admitted to
the ICU was 34%. Time to ICU admission and time to
mechanical ventilation are depicted in Figure 9C and
9D. Over the course of hospitalization, a total of 85 patients with SARS-CoV-2 CAP developed septic shock
and 98 patients developed ARDS. Time to septic shock
and time to ARDS are depicted in Figure 9E and 9F.
Mortality was much higher in comorbid patients, ranging from 16 to 36%. Figure 10 depicts crude mortality
by demographics and comorbidities.

Discussion
Our study indicates that SARS-CoV-2 CAP is present
in 90% of all patients hospitalized with COVID-19. We
previously described the clinical characteristics of hospitalized patients in the city of Louisville with CAP due
to the four endemic serotypes of coronaviruses.[11] The
most frequent serotype causing CAP was CoV-OC43,
followed by CoV-229E, CoV-HKU1, and CoV-NL63. At
this time, SARS-CoV-2 has emerged as the predominant coronavirus causing CAP. Hospitalized COVID-19
patients without CAP constitute a heterogenous population. The most common admission diagnoses in
patients without CAP included labor & delivery and
trauma. In the majority of these patients COVID-19
was present as an asymptomatic infection.
Among the patients hospitalized with SARS-CoV-2 in

ULJRI | https://ir.library.louisville.edu/jri/vol4/iss1/72

Table 5. Cardiac and cardiovascular events in patients hospitalized
due to SARS-CoV-2 CAP.

Variable

n (%)

Total patients
New arrhythmia
Heart failure
Cardiac arrest
Acute worsening of chronic arrhythmia
Cardiogenic shock
Acute myocardial infarction
Pulmonary edema
Cerebrovascular accident
Pulmonary embolism
Deep vein thrombosis
Myocarditis

632
52 (8)
25 (4)
20 (3)
20 (3)
15 (2)
13 (2)
13 (2)
7 (1)
6 (1)
6 (1)
2 (<1)

the city of Louisville, adults of black race or Hispanic
ethnicity are overrepresented in relation to the census population of the city. Our study supports data
from other areas of the Unites States indicating a higher
percentage of black patients hospitalized with COVID19.[12]
Hypertension was the most frequent comorbidity
in hospitalized patients with SARS-CoV-2 CAP in
Louisville. Patients with hypertension, as well as
patients with obesity, diabetes, renal disease, coronary artery disease, COPD, and cerebrovascular disease were overrepresented in the population hospitalized with SARS-CoV-2 CAP when compared to the
general Louisville population. Hypertension was also
reported as the most common comorbidity in hospitalized patients in a large CDC multicenter study.[13]
A clinical syndrome of CAP was the predominant clinical presentation of COVID-19 in hospitalized patients.
The most common signs and symptoms in our population were fever, cough, and shortness of breath. These
are the most frequent signs and symptoms for hospitalized patients with COVID-19 in the US.[13] Some of
our patients presented with a flu-like clinical syndrome
characterized by fever, sore throat, fatigue and muscle
aches. During the next winter season, the flu-like illnesses produced by SARS-CoV-2 will need to be added
to the differential diagnosis of flu-like illness produced
by other winter respiratory viruses. Surveillance data
on circulating respiratory viruses in the community
will be important to facilitate the clinical management
of patients with flu-like illness this winter. SARS-CoV-2
started to circulate in the Louisville community at the
end of the 2019-2020 winter season. Coincidental to
the emergence of SARS-CoV-2 in Louisville, we documented a significant decrease in the circulation of other
serotypes of coronavirus, as well as a decrease in respiratory syncytial virus, rhinovirus, and influenza.[14]
The decrease in common respiratory viruses at the end
of last winter was most likely related to the different
8
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Figure 6. The distribution of patients hospitalized with SARS-CoV-2 CAP in PSI risk classes (top-left) and the distribution of patients hospitalized
with SARS-CoV-2 CAP in CURB-65 scores (top-right) are shown in the top of the figure. The associated percentage of in-hospital mortality by
PSI risk class (bottom-left) and by CURB-65 score (bottom-right) are shown below.

steps implemented in the city related to social distancing, primarily, the closure of non-essential businesses.
Severity of CAP at time of hospitalization is usually
evaluated using the PSI score or the CURB-65 score.
When we applied these scores to our population of hospitalized patients with SARS-CoV-2 CAP, the CURB-65
score better discriminated risk of death during hospitalization, from 3% risk for death in patients with a
score of 0, to 70% risk for death for patients with a score
of 5. Physicians may use the CURB-65 to supplement
clinical judgment when evaluating severity and risk of
death in patients with SARS-CoV-2 CAP. One weakness
of our study is the lack of data regarding ambulatory
patients with COVID-19 in the city of Louisville, therefore we cannot evaluate the role of severity scores in
deciding ambulatory care.
On the first day of hospitalization, need for ICU care
was documented in 20% of our SARS-CoV-2 CAP population. A high proportion of patients hospitalized
ULJRI | https://ir.library.louisville.edu/jri/vol4/iss1/72

with COVID-19 requiring initial high level of care was
also documented in a large cohort study in the United
Kingdom.[15] Admission to the ICU during the first
day of hospitalization may indicate a rapid progression
of SARS-CoV-2 infection in some patients or may indicate that some patients may not look for early medical attention. The initial treatment strategies from the
time of study were not evidence-based, as there was a
lack of studies from the corresponding study period. It
is also important to note that several patients hospitalized with SARS-CoV-2 CAP were treated with hydroxychloroquine. This medication is not currently recommended for hospitalized patients, but a series of patients hospitalized at the beginning of the pandemic
were treated with hydroxychloroquine even though the
evidence for its efficacy was lacking.
Using the initial cycle threshold (Ct) levels, we estimated the SARS-CoV-2 viral load at the time of hospitalization in 405 patients with SARS-CoV-2 CAP. Ct val-

9
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Figure 7. Distribution of the lowest CT value from the N1, N2, and N3 gene. Lower CT values are analogous to higher viral loads. Level of viral
load was classified into high, intermediate, and low.

Figure 8. Kernel density heatmap of residential addresses of patients hospitalized with SARS-CoV-2 CAP. Four distinct areas of elevated risk
are identified in the dashed circles.

ULJRI | https://ir.library.louisville.edu/jri/vol4/iss1/72
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Figure 9. Time to event outcomes, in days. A) Time to discharge from admission, B) time to mortality from admission, C) time to ICU admission,
D) time to initiation of IMV, E) time to septic shock, F) time to ARDS.

ULJRI | https://ir.library.louisville.edu/jri/vol4/iss1/72
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Table 6. Number of patients with coinfections, micro-organisms, and culture sites in adults hospitalized with SARS-CoV-2 CAP.

Organism

Patients (n)

Culture site (n)

Community-acquired coinfections
Escherichia coli
Klebsiella pneumoniae
Haemophilus influenzae
Streptococcus pneumoniae
Acinetobacter spp.
Enterobacter spp.
Influenza B
Moraxella catarrhalis
Parainfluenza virus
Pseudomonas aeruginosa
Respiratory syncytial virus
MSSA
Streptococcus bovis
Streptococcus pyogenes
Candida spp.

7
3
2
2
1
1
1
1
1
1
1
1
1
1
1

Blood (2), urine (5)
Sputum (1), urine (2)
Sputum (2)
Sputum (2)
Sputum (1)
Urine (1)
BAL (1)
Sputum (1)
BAL (1)
Urine (1)
BAL (1)
Sputum (1)
Blood (1)
Blood (1)
Blood (1)

Hospital-acquired coinfections
MRSA
Enterobacter spp.
Klebsiella pneumoniae
Pseudomonas aeruginosa
Escherichia coli
Stenotrophomonas spp.
Citrobacter spp.
Serratia spp.
Candida spp.
Aspergillus spp.
Coronavirus OC43
MSSA

9
5
5
5
4
4
2
2
2
2
1
1

Blood (1), sputum (7), Urine culture (1)
Blood (2), sputum (3)
Sputum (3), BAL (1), urine culture (1)
Blood (1), sputum (2), BAL (1), Urine (1)
Sputum (1), urine (3)
Sputum (3), BAL (1)
Sputum (1), BAL (1)
Sputum (1), urine (1)
Blood (1), urine (1)
Sputum (2)
NP swab (1)
Sputum (1)

Abbreviations: BAL, bronchoalveolar lavage; MRSA, methicillin-resistant Staphylococcus aureus; MSSA, methicillin-susceptible Staphylococcus aureus; NP, nasopharyngeal.

ues are inversely proportional to the amount of the target nucleic acid in the sample.[16] We identified some
patients with high Ct values, indicating very low viral
loads at time of hospitalization. It has been suggested
that the concentration of viral RNA in throat swabs
may be already on the decline for some patients at the
time of initial presentation.[17]
The heatmap of patients hospitalized with SARS-CoV2 in the city of Louisville identifies areas of high relative risk that are very similar to areas that we previously identified as high risk for hospitalization due
to CAP.[2] The clustering of hospitalized patients with
CAP as well as SARS-CoV-2 CAP in the western section of the city is associated with census tracts where
the average population has low annual income and is
of predominantly black race.
Cardiovascular events at time of hospitalization or during hospitalization were documented in 19% of hospitalized patients with SARS-CoV-2 CAP. New arrhythmias were the most frequent cardiovascular event, taking place in 8% of the patients hospitalized with SARSCoV-2 CAP. Cardiovascular complications may be due
ULJRI | https://ir.library.louisville.edu/jri/vol4/iss1/72

to increased cardiac demand produced by the infection,
destabilization of vascular plaques due to systemic
inflammation, hypercoagulability due to endothelial
damage, or direct heart damage due to SARS-CoV2.[18]
A systematic review identified co-infections in 7%
of hospitalized COVID-19 patients.[19] We identified
co-infections in 8% of our SARS-CoV-2 CAP cohort;
25 were community-acquired and 42 were hospitalacquired. Viral respiratory infections such as influenza
can predispose patients to co-infections of the respiratory tract. SARS-CoV-2 seems to predispose patients to
infections in the respiratory tract but also outside of the
respiratory tract. As an example, our group reported
a case of a hospitalized patient with SARS-CoV-2 CAP
and concomitant Escherichia coli bacteremia due to a
prostatic abscess.[20]
Proper assessment of clinical outcomes is a crucial component of current research efforts in the field of COVID19. Studies of therapeutic interventions that evaluate clinical outcomes for all hospitalized patients with
COVID-19 may be biased by the heterogenous popu12
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Figure 10. Mortality by demographics and comorbid conditions. The percentage mortality in each group is displayed.

lation that is admitted to the hospital with the general
diagnosis of COVID-19. In our study of 632 hospitalized patients with SARS-CoV-2 and a clinical diagnosis of CAP, we evaluated five binary outcomes and six
time-to-event outcomes. The mean length of stay was 7
days, with an in-hospital mortality of 17%. For patients
in the ICU mortality was 34%. The ICU mortality in our
cohort is higher than the mortality of 26% reported in a
study of patients hospitalized to ICUs at 72 hospitals in
Italy.[21]
In conclusion, SARS-CoV-2 CAP is the primary reason
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for hospitalization of patients with COVID-19. Patients
with SARS-CoV-2 CAP account for 90% of COVID-19
hospitalizations with an in-hospital mortality of 17%.
Community members who are elderly, of black race,
Hispanic ethnicity, and having medical comorbidities
are at high risk for hospitalization. The primary medical comorbidities in our population were hypertension,
obesity, diabetes, renal disease and cerebrovascular disease. Future research in hospitalized patients with
COVID-19 should concentrate primarily on the development of new management and treatment strategies
for patients with SARS-CoV-2 CAP.

distributed under the terms of the Creative Commons Attribution 4.0 International License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium,
provided the original author and source are credited.

Published: December 7, 2020
Copyright: © 2022 The author(s). This original article is
brought to you for free and open access by ThinkIR: The University of Louisville’s Institutional Repository. For more information, please contact thinkir@louisville.edu. This article is

ULJRI | https://ir.library.louisville.edu/jri/vol4/iss1/72

Funding Source: The author(s) received no specific funding
for this work.
Conflict of Interest: All authors declared no conflict of interest in relation to the main objective of this work.

13

ULJRI

Characteristics and Outcomes of Adults Hospitalized with SARS-CoV-2 CAP

References
1. Wiersinga WJ, Rhodes A, Cheng AC, Peacock SJ,
Prescott HC. Pathophysiology, transmission, diagnosis, and
treatment of coronavirus disease 2019 (COVID-19): A review.
Jama 2020; 324(8):782-93. doi: 10.1001/jama.2020.12839.
PMID: 32648899.
2. Ramirez JA, Wiemken TL, Peyrani P, et al. Adults hospitalized with pneumonia in the United States: Incidence, epidemiology, and mortality. Clin Infect Dis 2017; 65(11):180612. doi: 10.1093/cid/cix647. PMID: 29020164.
3. Ranieri VM, Rubenfeld GD, Thompson BT, et al. Acute
respiratory distress syndrome: The berlin definition. JAMA
2012; 307(23):2526-33.
doi: 10.1001/jama.2012.5669.
PMID: 22797452.
4. National Institutes of Health.
Clinical presentation of people with SARS-CoV-2 infection.
Available at:
https://www.covid19treatmentguidelines.nih.gov/
overview/clinical-presentation/. Accessed 20 October 2020.
5. Fine MJ, Auble TE, Yealy DM, et al.
A prediction
rule to identify low-risk patients with community-acquired
pneumonia. N Engl J Med 1997; 336(4):243-50. doi:
10.1056/nejm199701233360402. PMID: 8995086.
6. Lim WS, van der Eerden MM, Laing R, et al. Defining community acquired pneumonia severity on presentation to hospital: An international derivation and validation study. Thorax 2003; 58(5):377-82. doi: 10.1136/thorax.58.5.377. PMID:
12728155.
7. United States Census Bureau. Welcome to Geocoder.
Available at: https://geocoding.geo.census.gov/geocoder/.
Accessed 17 September 2020.
8. Centers for Disease Control and Prevention. Behavioral
Risk Factor Surveillance System. Available at: https://www.
cdc.gov/brfss/index.html. Accessed 17 November 2020.

12. Price-Haywood EG, Burton J, Fort D, Seoane L. Hospitalization and mortality among black patients and white patients
with COVID-19. N Engl J Med 2020; 382(26):2534-43. doi:
10.1056/NEJMsa2011686. PMID: 32459916.
13. Garg S, Kim L, Whitaker M, et al. Hospitalization rates
and characteristics of patients hospitalized with laboratoryconfirmed coronavirus disease 2019 - COVID-NET, 14 states,
March 1-30, 2020. MMWR Morb Mortal Wkly Rep 2020;
69(15):458-64. doi: 10.15585/mmwr.mm6915e3. PMID:
32298251.
14. Bohn B. The incidence of common respiratory viruses
during the covid-19 pandemic: Results from the Louisville
COVID-19 Epidemiology Study. Univ Louisville J Respir Infect 2020; 4(1):Article 58. doi: 10.18297/jri/vol4/iss1/58.
15. Docherty AB, Harrison EM, Green CA, et al. Features
of 20 133 UK patients in hospital with COVID-19 using the
ISARIC WHO clinical characterisation protocol: Prospective
observational cohort study. BMJ 2020; 369:m1985. doi:
10.1136/bmj.m1985. PMID: 32444460.
16. Bordon J, Chung D, Krishnan P, Carrico R, Ramirez JA.
The importance of cycle threshold values in the evaluation of
patients with persistent positive PCR for SARS-CoV-2: Case
study and brief review. Univ Louisville J Respir Infect 2020;
4(1):Article 54. doi: 10.18297/jri/vol4/iss1/54.
17. Wölfel R, Corman VM, Guggemos W, et al. Virological
assessment of hospitalized patients with COVID-2019. Nature 2020; 581(7809):465-9. doi: 10.1038/s41586-020-2196x. PMID: 32235945.
18. Long B, Brady WJ, Koyfman A, Gottlieb M. Cardiovascular complications in COVID-19. Am J Emerg Med 2020;
38(7):1504-7. doi: 10.1016/j.ajem.2020.04.048. PMID:
32317203.

9. United States Census Bureau. American Community Survey 2014-2018 5-year estimates now available. Online, 2019.

19. Lansbury L, Lim B, Baskaran V, Lim WS. Coinfections in people with COVID-19: A systematic review
and meta-analysis. J Infect 2020; 81(2):266-75. doi:
10.1016/j.jinf.2020.05.046. PMID: 32473235.

10. Harris PA, Taylor R, Minor BL, et al. The REDCAP
consortium: Building an international community of software
platform partners. J Biomed Inform 2019; 95:103208. doi:
10.1016/j.jbi.2019.103208. PMID: 31078660.

20. Moore S. A patient with Escherichia coli bacteremia
and COVID-19 co-infection: A case report for the Louisville
COVID-19 Epidemiology Study. Univ Louisville J Respir Infect 2020; 4(1):Article 15. doi: 10.18297/jri/vol4/iss1/15.

11. Arnold F, Burns M, Mahmood K, et al. Endemic human coronaviruses in hospitalized adults with communityacquired pneumonia: Results from the Louisville Pneumonia
Study. Univ Louisville J Respir Infect 2020; 4(1):Article 1. doi:
10.18297/rgh/vol4/iss1/1.

21. Grasselli G, Zangrillo A, Zanella A, et al. Baseline
characteristics and outcomes of 1591 patients infected with
SARS-CoV-2 admitted to ICUs of the Lombardy region, Italy.
Jama 2020; 323(16):1574-81. doi: 10.1001/jama.2020.5394.
PMID: 32250385.

ULJRI | https://ir.library.louisville.edu/jri/vol4/iss1/72

14

